主页 > 生命科学 >
【medical-news】类前列腺素EP4受体：肺动脉高压治
Rationale: Iloprost is effective for the treatment of pulmonary hypertension. It acts through elevation of cAMP by binding to the prostacyclin receptor (IP receptor). However, there is evidence that patients with severe pulmonary hypertension have decreased expression of the IP receptor in the remodeled pulmonary arterial smooth muscle.
Objectives: We hypothesized that prostanoid receptors other than the IP receptor are involved in signal transduction by iloprost.
Methods: Immunoblotting was used to detect the IP and prostanoid EP4 receptor in lung tissue from idiopathic pulmonary arterial hypertension (IPAH) patients, and immunohistochemistry was used to detect these receptors in lung sections from rats treated with monocrotaline (MCT28d). Protein and mRNA were isolated from pulmonary arterial smooth muscle cells (PASMCs) from control and MCT28d rats treated with AH6809 (an EP2 receptor antagonist) and AH23848 (an EP4 receptor antagonist) in combination with iloprost. Intracellular cAMP was also assessed in these tissues.
Results: IP receptor expression was reduced in IPAH patient lung samples and MCT28d rat lungs compared to the controls. RT-PCR and immunoblotting of MCT28d rat PASMC extracts revealed scant expression of the IP receptor but stable expression of EP4 receptor, compared to controls. Iloprost-induced elevation in intracellular cAMP in PASMCs was dose-dependently reduced by AH23848, but not by AH6809.
Conclusion: Iloprost mediates vasodilatory functions via the EP4 receptor in the case of low IP receptor expression associated with pulmonary arterial hypertension. This is a previously unrecognized mechanism for iloprost, and illustrates that the EP4 receptor may be a novel therapeutic approach for the treatment of pulmonary arterial hypertension.
Key words: prostanoid EP4 receptor, iloprost, pulmonary artery hypertension
Ying-Ju Lai1, Soni Savai Pullamsetti2, Eva Dony1, Norbert Weissmann1, Ghazwan Butrous3, Gamal-Andre Banat4, Hossein Ardeschir Ghofrani1, Werner Seeger1, Friedrich Grimminger1, and Ralph Theo Schermuly2*
1 University of Giessen Lung Centre (UGLC), Giessen, Germany, 2 University of Giessen Lung Centre (UGLC), Giessen, Germany; Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany, 3 Kent Institute of Medicine and Health Sciences, University of Kent, Kent, United Kingdom, 4 Department of Hematology and Oncology, University of Giessen, Giessen, Germany
Published ahead of print on May 8, 2008
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-29 22:20
医学,生命科学网